Ch.	eet	1	of	1
SΠ	eet	1	OI	1

0	(Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 10448-217002	Application No. 10/766,773		
UL 1	11.4 *	Information Disclosure Statement by Applicant		Applicant LaRosa et al.		
	(Use several s	heets if necessary)	Filing Date	Group Art Unit		

	U.S. Patent Documents							
Examiner Initial								
AB	AA	6,727,349	4/27/2004	LaRosa et al.				

	Foreign Patent Documents or Published Foreign Patent Applications							
Examiner	Desig.	Document	Publication	Country or			Trans	lation
Initial	ID	Number	Date	Patent Office	Class	Subclass	Yes	No

(Other D	ocuments (include Author, Title, Date, and Place of Publication)
Examiner Initial	Desig. ID	Document
	ΛĐ	Office Action received in Mexican Application No. 2002-007449, dated May 4, 2005.

Examiner Signature /Agnieszka Boesen/	Date Considered 09/22/2006
EVANUED, Initials situation considered Draw line through situation if no	t in conformance and not considered. Include conv. of this form with

EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

PTO-1449 REPRODUCED	ATTORNEY DOCKET NO. 1855.1052-028	APP	LICATION NO.	
INFORMATION DISCLOSURE CITATION IN AN APPLICATION	FIRST NAMED INVENTOR Gregory J. LaRosa		FILING DATE	
December 16, 2003 (Use several sheets if necessary)	EXAMINER	CONFI	RMATION NO.	GROUP

		U.S	. PATENT DOCUMENTS	
EXAM- INER INI- TIAL	REF. NO.	DOCUMENT NUMBER Number-Kind Code (if known)	ISSUE DATE / PUBLICATION DATE MM-DD-YYYY	NAME OF PATENTEE OR APPLICANT OF CITED DOCUMENT
AB	AA	6,084,075	07-04-2000	Lind, et al.
AB	AB	5,543,503	08-06-1996	Chuntharapai, et al.
AB	AC	5,440,021	08-08-1995	Chuntharapai, et al.
AB	AD	5,859,205	01-12-1999	Adair, et al.
AB	AE	5,693,762	12-02-1997	Queen, et al.
AB	AF	5,693,761	12-02-1997	Queen, et al.
AB	AG	5,585,089	12-17-1996	Queen, et al.
AB	АН	5,225,539	07-06-1993	Winter
AB	AJ	4,816,397	03-28-1989	Boss, et al.
AB	AJ	4,816,567	03-28-1989	Cabilly, et al.
AB	AK	5,707,815	01-13-1998	Charo, et al.
AB	AA2	5,571,713	11-05-1996	Lyle, et al.
AB	AB2	5,985,279 \	11-16-1999	Waldmann, et al.
	AC2			
	AD2			
	AE2			
	AF2			
	AG2			
	AH2			
	Al2			
	AJ2			
	AK2			
	AA3			
	AB3			
L	AC3			

·		
EXAMINER /Agnieszka Boesen/	DATE CONSIDERED	09/22/2006

•	
- 5	n٠

PTO-1449 REPRODUCED

INFORMATION DISCLOSURE CITATION IN AN APPLICATION

December 16, 2003

(Use several sheets if necessary)

ATTORNEY DOCKET NO. 1855.1052-028	APP	LICATION NO.	
FIRST NAMED INVENTOR Gregory J. LaRosa		FILING DATE	

EXAMINER CONFIRMATION NO. GROUP

		F	OREIGN PATENT D	OCUMENTS		
		DOCUMENT NUMBER Country Code-Number-Kind Code (if known)	DATE MM-DD-YYYY	NAME OF PATENTEE OR APPLICANT OF CITED DOCUMENT	TRANS YES	LATION NO
AB	AL	PCT WO 95/08576	03-30-1995	LIPP, Martin		Х
AB	AM	PCT WO 99/15666	04-01-1999	ICOS Corporation		
AB	AN	PCT WO 97/31949	09-04-1997	Pharmacia & UpJohn AB and Conseio Superior De Investigaciones		
AB	AO	PCT WO 95/19436	07-20-1995	The Regents of the University of California		
AB	ΑР	PCT WO 98/44953	10-15-1998	Max-Planck-Gesellschaft Zur Förderung Der Wissenschaften E.V.		
AB	AQ	PCT WO 94/09128	04-28-1994	Mallinckrodt Medical, Inc.		
AB	AL2	PCT WO 91/09967	07-11-1991	Celltech Limited		
AB	AM2	PCT WO 00/05265	02-03-2000	LeukoSite, Inc.	_	
AB	AN2	PCT WO 97/47319	12-18-1997	Progenics Pharmaceuticals, Inc., and Aaron Diamond Aids Research Centre		
AB	AO2	PCT WO 94/12214	06-09-1994	Protein Design Labs, Inc.		
AB	AP2	PCT WO 98/42360 🗸	10-01-1998	Massachusetts Institute of Technology		
	AQ2					
	AL3	·				
	AM3					
	AN3	·				
	AO3					
	AP3					
	AQ3					
	AL4					
	AM4					
	AN4					

EXAMINER	/Agnieszka Boesen/	DATE CONSIDERED 09/22/2006	
II			

PTO-1449 REPRODUCED	ATTORNEY DOCKET NO. APPLICATION NO. 1855.1052-028		
INFORMATION DISCLOSURE CITATION IN AN APPLICATION	FIRST NAMED INVENTOR FILING DATE Gregory J. LaRosa		
December 16, 2003	EXAMINER	CONFIRMATION NO.	GROUP
(Use several sheets if necessary)			

		OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)
AB	AR	Förster, R. et al., "A general method for screening mAbs specific for G-protein coupled receptors as exemplified by using epitope tagged BLR1-transfected 293 cells and solid-phase cell ELISA", Biochemical and Biophysical Research Communications 196(3):1496-1503 (1993).
AB	AS	Boring, L. et al., "Decreased lesion formation in CCR2" mice reveals a role for chemokines in the initiation of atherosclerosis," Nature 394(27):894-897 (1998).
AB	AT	Ylä-Herttuala, S. et al., "Expression of monocyte chemoattractant protein 1 in macrophage-rich areas of human and rabbit atherosclerotic lesions," <i>Proc. Natl. Acad. Sci.</i> , USA 88:5252-5256 (1991).
AB	AU	Taubman, M.B. et al., "JE mRNA Accumulates Rapidly in Aortic Injury and in Platelet-Derived Growth Factor-Stimulated Vascular Smooth Muscle Cells," Circulation Research 70(2):314-325 (1992).
AB	AV	Feng, A. et al., "Red Wine Inhibits Monocyte Chemotactic Protein-1 Expression and Modestly Reduces Neointimal Hyperplasia After Balloon Injury in Cholesterol-Fed Rabbits," Circulation 100:2254-2259 (1999).
AB	AW	Lukacs, N.W. et al., "Production of Monocyte Chemoattractant Protein-1 and Macrophage Inflammatory Protein-1α by Inflammatory Granuloma Fibroblasts," <i>American Journal of Pathology</i> 144(4):711-718 (1994).
AB	AX	Koch, A.E., et al., "Enhanced Production of Monocyte Chemoattractant Protein-1 in Rheumatoid Arthritis," The Jour. of Clin. Invest. 90:772-779 (1992).
AB	AY	Harigai, M. et al., "Monocyte Chemoattractant Protein-1 (MCP-1) in Inflammatory Joint Diseases and Its Involvement in the Cytokine Network of Rheumatoid Synovium," Clin. Immun. and Immunopathology 69(1):83-91 (1993).
AB	ΑZ	Villiger, P.M. et al., "Production of Monocyte Chemoattractant Protein-1 by Inflamed Synovial Tissue and Cultured Synoviocytes," J. Immunol. 149(2):722-727 (1992).
AB	AR2	Reinecker, H.C. et al., "Monocyte-Chemoattractant Protein 1 Gene Expression in Intestinal Epithelial Cells and Inflammatory Bowel Disease Mucosa," Gastroenterology 108(1):40-50 (1995).
АВ	AS2	Nelken, N.A. et al., "Monocyte Chemoattractant Protein-1 in Human Atheromatous Plaques," J. Clin. Invest. 88:1121-1127 (1991).

/Agnieszka Boesen/	DATE CONSIDERED 09/22/2006		

PTO-1449 REPRODUCED	ATTORNEY DOCKET NO. 1855.1052-028	АРР	LICATION NO.	
INFORMATION DISCLOSURE CITATION IN AN APPLICATION	FIRST NAMED INVENTOR Gregory J. LaRosa		FILING DATE	
December 16, 2003 (Use several sheets if necessary)	EXAMINER	CONF	IRMATION NO.	GROUP

		OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)
AB	AT2	Grewal, I.S. et al., "Transgenic Monocyte Chemoattractant Protein-1 (MCP-1) in Pancreatic Islets Produces Monocyte-Rich Insulitis Without Diabetes," J. Immunol. 159:401-408 (1997).
AB	AU2	Yu, X. et al., "Elevated expression of monocyte chemoattractant protein 1 by vascular smooth muscle cells in hypercholesterolemic primates," <i>Proc. Natl. Acad. Sci., USA</i> 89:6953-6957 (1992).
AB	AV2	Berman, J.W. et al., "Localization of Monocyte Chemoattractant Peptide-1 Expression in the Central Nervous System in Experimental Autoimmune Encephalomyelitis and Trauma in the Rat," J. Immunol. 156:3017-3023 (1996).
AB	AW2	Lukacs, N.W. et al., "The Production of Chemotactic Cytokines an Allogeneic Response," Amer. Jour. of Pathology 143(4):1179-1188 (1993).
AB	AX2	Christensen, P.J. et al., "Characterization of the Production of Monocyte Chemoattractant Protein-1 and IL-8 in an Allogeneic Immune Response," The Journal of Immunology 151(3):1205-1213 (1993).
АВ	AY2	Rand, M.L. et al., "Inhibition of T Cell Recruitment and Cutaneous Delayed-Type Hypersensitivity-Induced Inflammation with Antibodies to Monocyte Chemoattractant Protein-1," Amer. Jour. of Pathology, 148(3):855-864 (1996).
AB	AZ2	Jones, M.L. and Warren, J.S., "Monocyte Chemoattractant Protein 1 in a Rat Model of Pulmonary Granulomatosis," <i>Laboratory Investigation</i> 66(4):498-503 (1992).
AB	AR3	Lloyd, C.M. et al., "Role of MCP-1 and RANTES in inflammation and progression to fibrosis during murine crescentic nephritis," Journal of Leukocyte Biology 62:676-680 (1997).
AB	AS3	Flory, C.M. et al., "Pulmonary Granuloma Formation in the Rat is Partially Dependent on Monocyte Chemoattractant Protein 1," Laboratory Invest., 69(4):396-404 (1993).
AB	AT3	Jones, M.L. et al., "Potential Role of Monocyte Chemoattractant Protein 1/JE In Monocyte/Macrophage- Dependent IgA Immune Complex Alveolitis in the Rat," J. Immunol. 149(6):2147-2154 (1992).
АВ	AU3	Gu, L. et al., "Absence of Monocyte Chemoattractant Protein-1 Reduces Atherosclerosis in Low Density Lipoprotein Receptor-Deficient Mice," Molecular Cell, 2(2):275-281 (1998).
AB	AV3	Tesch, G.H., et al., "Monocyte chemoattractant protein-1 promotes macrophage-mediated tubular injury, but not glomerular injury, in nephrotoxic serum nephritis," J. Clin. Invest. 103(1):73-80 (1999).

	EXAMINER /	Agnieszka Boesen/	DATE CONSIDERED	09/22/2006
١			<u></u>	

PTO-1449 REPRODUCED	ATTORNEY DOCKET NO. APPLICATION NO. 1855.1052-028		
INFORMATION DISCLOSURE CITATION IN AN APPLICATION	FIRST NAMED INVENTOR FILING DATE Gregory J. LaRosa		
December 16, 2003	EXAMINER	CONFIRMATION NO.	GROUP
(Use several sheets if necessary)			

	OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)		
AB	AW3	Lu, B., et al., "Abnormalities in Monocyte Recruitment and Cytokine Expression in Monocyte Chemoattractant Protein 1-deficient Mice," J. Exp. Med. 187(4):601-608 (1998).	
AB	AX3	Rutledge, B.J. et al., "High Level Monocyte Chemoattractant Protein-1 Expression in Transgenic Mice Increases Their Susceptibility to Intracellular Pathogens," J. Immunol. 155:4838-4843 (1995).	
AB	AY3	Gunn, M.D. et al., "Monocyte Chemoattractant Protein-1 Is Sufficient for the Chemotaxis of Monocytes and Lymphocytes in Transgenic Mice but Requires an Additional Stimulus for Inflammatory Activation," J. Immunol. 158:376-383 (1997).	
AB	AZ3	Chensue, S.W. et al., "Role of Monocyte Chemoattractant Protein-1 (MCP-1) in Th1 (Mycobacterial) and Th2 (Schistosomal) Antigen-Induced Granuloma Formation," J. Immunol. 157:4602-4608 (1996).	
AB	AR4	Lukacs, N.W. et al., "Differential Recruitment of Leukocyte Populations and Alteration of Airway Hyperreactivity by C-C Family Chemokines in Allergic Airway Inflammation," J. Immunol. 158:4398-4404 (1997).	
AB	AS4	Tang, W.W. et al., "Chemokine Expression in Experimental Tubulointerstitial Nephritis," J. Immunol. 159:870-876 (1997).	
AB	AT4	Fujinaka, H. et al., "Suppression of Anti-Glomerular Basement Membrane Nephritis by Administration of Anti-Monocyte Chemoattractant Protein-1 Antibody in WKY Rats," Jour. of the Amer. Soc. of Nephrology 8:1174-1178 (1997).	
AB	AU4	Lloyd, C.M., et al., "RANTES and Monocyte Chemoattractant Protein-1 (MCP-1) Play an Important Role in the Inflammatory Phase of Crescentic Nephritis, but Only MCP-1 Is Involved in Crescent Formation and Interstitial Fibrosis," J. of Exp. Med. 185(7):1371-1380 (1997).	
AB	AV4	Furukawa, Y. et al., "Anti-Monocyte Chemoattractant Protein-1/Monocyte Chemotactic and Activating Factor Antibody Inhibits Neointimal Hyperplasia in Injured Rat Carotid Arteries," Circulation Research 84:306-314 (1999).	
AB	AW4	Zisman, D.A. et al., "MCP-1 Protects Mice in Lethal Endotoxemia," J. Clin. Invest. 99(12):2832-2836 (1997).	
AB	AX4	Schimmer, R.C., et al., "Streptococcal Cell Wall-Induced Arthritis: Requirements for IL-4, IL-10, IFN-γ, and Monocyte Chemoattractant Protein-1," J. Immunol. 160:1466-1471 (1998).	

Agnieszka Boesen/	DATE CONSIDERED 09/22/2006

PTO-1449 REPRODUCED	ATTORNEY DOCKET NO. 1855.1052-028	APPLICATION NO.
INFORMATION DISCLOSURE CITATION IN AN APPLICATION	FIRST NAMED INVENTOR FILING DATE Gregory J. LaRosa	
December 16, 2003	EXAMINER	CONFIRMATION NO. GROUP
(Use several sheets if necessary)	<u> </u>	

	OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)		
AB	AY4	Ogata, H. et al., "The Role of Monocyte Chemoattractant Protein-1 (MCP-1) in the Pathogenesis of Collagen-Induced Arthritis in Rats," J. Pathol. 182:106-114 (1997).	
AB	AZ4	Huffnagle, G.B. et al., "The Role of Monocyte Chemotactic Protein-1 (MCP-1) in the Recruitment of Monocytes and CD4 ⁺ T Cells During a Pulmonary Cryptococcus Neoformans Infection," J. Immunol. 155:4790-4797 (1995).	
AB	AR5	Gong, J. et al., "An Antagonist of Monocyte Chemoattractant Protein 1 (MCP-1) Inhibits Arthritis in the MRL-lpr Mouse Model," J. Exp. Med. 186(1):131-137 (1997).	
AB	AS5	Boring, L. et al., "Impaired Monocyte Migration and Reduced Type 1 (Th1) Cytokine Responses in C-C Chemokine Receptor 2 Knockout Mice," J. Clin. Invest. 100(10):2552-2561 (1997).	
AB	AT5	Kuziel, W.A. et al., "Severe reduction in leukocyte adhesion and monocyte extravasation in mice deficient in CC chemokine receptor 2," Proc. Natl. Acad. of Sci., USA 94(22):12053-12058 (1997).	
AB	AU5	Kurihara, T. et al., "Defects in Macrophage Recruitment and Host Defense in Mice Lacking the CCR2 Chemokine Receptor," J. Exp. Med. 186(10):1757-1762 (1997).	
AB	AV5	Jiang, Y. et al., "Chemokine receptor expression in cultured glia and rat experimental allergic encephalomyelitis," J. Neuroimmunology 86:1-12(1998).	
AB	AW5	Chuntharapai et al., "Generation of Monoclonal Antibodies to Chemokine Receptors", Methods in Enzymology 288: 15-27 (1997).	
AB	AX5	Monteclaro, Felipe S. and Charo, Israel F., "The Amino-Terminal Domain of CCR2 Is Both Necessary and Sufficient for High Affinity Binding of Monocyte Chemoattractant Protein 1", The Journal of Biological Chemistry 272(37):23186-23190 (1997).	
AB	AY5	Qin, Shixin et al., "Expression of Monocyte Chemoattractant Protein-1 and Interleukin-8 Receptors on Subsets of T Cells: Correlation with Transendothelial Chemotactic Potential," Eur. J. Immonol. 26:640-647 (1996).	
AB	AZ5	Yamagami, Shinsuke et al., "cDNA Cloning and Functional Expression of a Human Monocyte Chemoattractant Protein 1 Receptor," Biochemical and Biophysical Research Communications 202(2):1156-1162 (1994).	

EXAMINER	/Agnieszka Boesen/	DATE CONSIDERED	09/22/2006	·

PTO-1449 REPRODUCED	ATTORNEY DOCKET NO. APPLICATE 1855.1052-028			
INFORMATION DISCLOSURE CITATION IN AN APPLICATION	FIRST NAMED INVENTOR Gregory J. LaRosa		ILING DATE	
December 16, 2003 (Use several sheets if necessary)	EXAMINER	CONFIRMATION NO.	GROUP	

		OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)
AB	AR6	Charo, Israel, F. et al., "Molecular Cloning and Functional Expression of Two Monocyte Chemoattractant Protein 1 Receptors Reveals Alternative Splicing of the Carboxyl-Terminal Tails," Proc. Natl. Acad. Sci., USA. 91:2752-2756 (1994).
AB	AS6	Aragay, A.M. et al., "Monocyte Chemoattractant Protein-1-Induced CCR2B Receptor Desensitization Mediated by the G Protein-Coupled Receptor Kinase 2," Proc. Natl. Acad. Sci. USA, 95:2985-2990 (1998).
AB	AT6	Frade, Jose M.R. et al., "Characterization of the CCR2 Chemokine Receptor: Functional CCR2 Receptor Expression in B Cells," J. Immunol. 159(11):5576-5584 (1997).
AB	AU6	Frade, Jose M.R. et al., "The Amino-Terminal Domain of the CCR2 Chemokine Receptor Acts as Coreceptor for HIV-1 Infection," J. Clin. Invest. 100(3):497-502 (1997).
АВ	AV6	Wong, Lu-Min et al., "Organization and Differential Expression of the Human Monocyte Chemoattractant Protein 1 Receptor Gene," The Journal of Biological Chemistry 272(2):1038-1045 (1997).
AB	`AW6	Kurihara, Takao and Bravo, Rodrigo, "Cloning and Functional Expression of mCCR2, a Murine Receptor for the C-C Chemokines JE and FIC," <i>The Journal of Biological Chemistry</i> 271(20):11603-11606 (1996).
AB	AX6	Grimm, M.C. et al., "Enhanced expression and production of monocyte chemoattractant protein-1 in inflammatory bowel disease mucosa," <i>Journal of Leukocyte Biology</i> 59:804-812 (1996).
AB	AY6	Izikson, L. et al., "Resistance to Experimental Autoimmune Encephalomyelitis in Mice Lacking the CC Chemokine Receptor (CCR)2," J. Exp. Med. 192(7):1075-1080 (2000).
AB	AZ6	Fife, B.T. et al., "CC Chemokine Receptor 2 Is Critical for Induction of Experimental Autoimmune Encephalomyelitis," J. Exp. Med. 192(6):899-905 (2000).
AB	AR7	Sanz, I., et al., "Evidence That Autoantibodies Can Be Unmutated Copies of Germline Genes," The Journal of Immunology 142(3):883-887 (1989).
AB	AS7	Chastagner, P., et al., "Cloning of a gene encoding a lupus-associated human autoantibody V _k region using the polymerase chain reaction and degenerate primers," Gene 101:305-306 (1991).
AB	AT7	Chothia, C., et al., "Conformations of immunoglobulin hypervariable regions," Nature 342:877-883 (1989).

	·		
Agnieszka	Boesen/	DATE CONSIDERED 09/22/2006	

PTO-1449 KEPRODUCED	ATTORNEY DOCKET NO. APPLICATION NO. 1855.1052-028			
INFORMATION DISCLOSURE CITATION IN AN APPLICATION	FIRST NAMED INVENTOR Gregory J. LaRosa FILING D		ATE	
December 16, 2003 (Use several sheets if necessary)	EXAMINER	CONFIRMATION NO.	GROUP	

		OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)		
AB	AU7	Welt, et al., "Targeting CCR-2 or CD18 Inhibits Experimental in-Stent Restenosis in Primates. Inhibitory Potential Depends on Type of Injury and Leukocytes Targeted", Circulation-Journal of the American Heart Association (Abstracts from Scientific Sessions 2000), 102(18): II-247, Abstract 1206 (2000).		
AB	AV7	Huston, James S., et al., "Engineered antibodies take center stage", Human Antibodies, 10:127-142 (2001).		
AB	AW7	Reichert, Janice M., "Monoclonal antibodies in the clinic", Nature Biotechnology, 19: 819-822 (2001).		
AB	AX7	Rudikoff, S., et al., "Single amino acid substitution altering anitgen-binding specificity," Proc. Natl. Acad. Sci USA, 79: 1979-1983 (1982).		
AB	AY7	Paul, William E., "Fundamental Immunology," Raven Press NY, Chapter 8, page 242 (1993).		
AB	AZ7	Berzofsky, J.A., et al., "Immunogenicity and Antigen Structure," Fundamental Immunology, 8: 242 (1993).		
AB	AR8	Johnston, B., et al., "Chronic inflammation upregulates chemokine receptors and induces neutrophil migration to monocyte chemoattractant protein-1," J. Clin. Invest., 103(9): 1269-1276 (1999).		

EXAMINER /Agnieszka Boesen/	DATE CONSIDERED 09/22/2006
/ Ingilitablika Doctorii	09/22/2006